


March 23-25, 2026 | San Diego, CA

www.innate-killer.com

REGISTER BY
DECEMBER 19
TO SAVE UP TO
\$1,000



11th Annual

Innate Killer Summit

Advancing NK Cell Therapies & Engagers from Concept to Clinic

Driving Long-Term Persistence, Clinical Efficacy & Scalability, Across Autoimmunity & Oncology, to Spearhead an Investment Revival in NK Therapies for Patients in Need

Expert Speakers Include:



Henri Bayle
Chief Scientific and
Development Officer
& Cofounder
NKILT Therapeutics



Nick Veomett
Vice President,
Corporate
Development &
Program Lead
Artiva



Frank Borriello
Chief Executive
Officer
**Alloplex
Biotherapeutics**



Nina Horowitz
Chief Executive
Officer
ImmuneBridge



Yi Jin
Chief Executive
Officer
GeCell Therapeutics



Kanya Rajangam
President, Chief
Medical Officer &
Head of Research &
Development
Senti Bio

“The conference was excellent and the best part for me was the opportunity to meet experts in the field, including potential new collaborators”

Founder & Chief Scientific Officer, **Indaptus Therapeutics**

+1 (617) 455-4188 @ info@hansonwade.com

www.innate-killer.com Cell & Gene Therapy Event Series



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Welcome to Your Exclusive Opportunity to Network with Industry Leaders & Investors in the Natural Killer Cell Landscape



11th Annual

Innate Killer Summit

March 23-25, 2026 | San Diego, CA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

With the NK community holding strong in the determination to prove the potential of NK therapies, the industry is still alive and striving to bring patient-safe clinical therapies to those with autoimmune and oncology indications. Time is of the essence for drug developers in this space to build robust proof of concept and clinical data packages to revitalize the investor confidence needed to support the clinical development of these essential but complex therapies.

Returning to San Diego for its 11th year, the **Innate Killer Summit** is your must-attend forum to gain **cutting edge scientific data** and **first-hand insights on clinical trial strategies**. Additionally, it is the perfect platform to develop critical business partnerships that will foster your future clinical progress, and aid strategic conversations with investors.

As the only dedicated, and longest tenured meeting for NK-based therapies, don't miss your opportunity to take part in even more interactive sessions in 2026. Solution-led case studies will equip you with actionable insights to **better optimize early developments of scalable processes** that support clinical development and enable patient demand to be met across autoimmunity and oncology.

There is valuable content for your whole team across the stages of development. From academic leaders like **Neil Sheppard** and **MD Anderson Lab** spotlighting their experiences, and innovators like **NKILT Therapeutics**, **Artiva Biotherapeutics**, **NÖK Therapeutics**, and more, detailing lessons learned moving from discovery through to the clinic, these sessions are set to fast track your NK pipelines into the clinic!

Stay ahead of the curve and benchmark advances across **in vivo development**, **autoimmune targeting**, and **innovative manufacturing strategies** to keep cost of goods down, while proving the potential of your NK pipeline with robust proof of concept data to support IND submissions.

What Our Attendees have to Say

“The outstanding presentations and discussions focused on NK biology and engineering were highly valuable to me as an NK researcher. It was a great opportunity to network with NK experts from all around the world”

Physician-Scientist
Instructor, **Stanford University**

“What always stands out with the Innate Killer Summit are the more focused group discussions and a chance to speak to the decision makers over multiple sessions”

Director & Co-founder, **East Ocyon Bio**

Key Benefits of Attending



Gain Exclusive Insights from the Foremost Leaders in Innate Immunity
Hear directly from CEOs and scientific pioneers across the field, including leaders from **ImmuneBridge**, **NKILT Therapeutics**, **Artiva Biotherapeutics**, and **NÖK Therapeutics**, as they share the breakthroughs redefining NK- and innate-cell innovation.



Access the Latest Clinical Data Driving Confidence in Innate Cell Therapies
Explore the newest results from NK, iNKT, CAR-NK, and next generation innate programs presented by trailblazing organizations such as **Glycostem**, **Senti Bio**, and **NKore BioTherapeutics**.



Strengthen Your Strategic & Scientific Decision-Making
Learn practical approaches to manufacturing, translational science, engineering, and **AI-led** development from experts advancing platforms at **ImmuneBridge**.



Explore Deep Dive Workshops
Explore two focused workshops that equip you with practical strategies to strengthen NK therapy development, from **optimizing manufacturing and scalability** to **applying advanced biomarkers** and translational tools that de-risk programs and accelerate clinical success.



Understand the Evolving Investment & Commercial Landscape
Hear directly from strategic voices from groups to understand current funding priorities and how to position your pipeline for success.



+1 (617) 455-4188



info@hansonwade.com



www.innate-killer.com



Cell & Gene Therapy Event Series



What's New for 2026?



11th Annual Innate Killer Summit

March 23-25, 2026 | San Diego, CA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Key Sessions not to Miss

CEO Think Tank

Don't miss this unique, high-impact conversation in which leading CEO's reveal the strategic decisions, challenges, and opportunities shaping the future of innate immunity.

1



ImmuneBridge



decell 德信科技



NÖK
THERAPEUTICS



NKORE
Biotherapeutics



NÖK
THERAPEUTICS

Durable Long-Term Survival Following Autologous NK-Cell Consolidation in Multiple Myeloma: Phase I Data with Extended Follow-Up

An in-depth presentation of durability outcomes, high-risk cohort performance, and the mechanistic and clinical insights supporting NK-cell consolidation as a next-generation strategy in multiple myeloma.

2

Robert Lewis, Chief Executive Officer & Co-Founder, NÖK Therapeutics



NKILT
THERAPEUTICS

Panel Discussion: Innovation Pathways from Autologous to Allogeneic to *In Vivo*

What's the development roadmap for the next decade in cell and gene therapies, and how do technologies build on one another rather than compete?

3

Henri Bayle, Chief Scientific and Development Officer & Cofounder, NKILT Therapeutics

Chris Horan, Chief Technical Officer, Artiva Bio



artiva

Clinical Insights for 2026

NKORE
BioTherapeutics

SENTI BIO

artiva

glycostem

NÖK
THERAPEUTICS

Showcase Your Scientific Poster



Share your latest findings and contribute to the continued advancement of innate immunity and NK-cell innovation. Present your cutting-edge research to a community of leading scientists, decision makers, and industry experts driving the field forward.

Register your place to submit an abstract for review to showcase your poster*

*Please visit the website for the T&Cs for presenting a poster

3

+1 (617) 455-4188

@ info@hansonwade.com

www.innate-killer.com

Cell & Gene Therapy Event Series

hansonwade

Your Expert Speakers



11th Annual

Innate Killer Summit

March 23-25, 2026 | San Diego, CA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Frank Borriello
Chief Executive Officer
Alloplex Biotherapeutics



Vasil Galat
Chief Executive &
Scientific Officer
Artec Biotech



Chris Horan
Chief Technical Officer
Artiva Biotherapeutics



Nick Veomett
Vice President, Corporate
Development & Program
Lead
Artiva Biotherapeutics



Prasad Krishnamurthy
Chief Scientific Officer
East Ocyon Bio



Yi Jin
Chief Executive Officer
GeCell Therapeutics



Adil Duru
Director of Business
Development
Glycostem



Monica Raimo
Director of Product &
Process Development
Glycostem



James Liu
Research Scientist
ImmuneBridge



Nina Horowitz
Chief Executive Officer
ImmuneBridge



Stefanie Mandl-Cashman
Chief Scientific Officer
Indapta Therapeutics



Hongxia Zhang
Independent Expert



Pinaki Prosad Banerjee
Director & Assistant
Professor, Laboratory of
Adoptive Cell Therapy
Platform, Stem Cell
Translational Research
**MD Anderson Cancer
Center, University of
Texas**



Henri Bayle
Chief Scientific and
Development Officer &
Cofounder
NKILT Therapeutics



Tracy Ryan
Founder
NKore BioTherapeutics



Robert Lewis
Chief Executive Officer &
Co-Founder
NÖK Therapeutics



Brian Garrison
Vice President of
Research
Senti Bio



Kanya Rajangam
President, Chief Medical
Officer & Head of
Research & Development
Senti Bio



Neil Sheppard
Director of Research
Technologies & Innovation
at the Center for Cellular
Immunotherapies
**University of
Pennsylvania**



Yansen Xiao
Postdoctoral Researcher
**University of
Pennsylvania**



Pre-Conference Workshop Day

Monday, March 23

Registration & Morning Coffee

9.00

Morning Session

9.30 - 12.30

Optimizing Donor Variability, Cryopreservation, Bioreactors & Scalability to Build Reliable Manufacturing Processes for Clinical Success

Advancing cell and gene therapies from preclinical to clinical stages requires tackling critical manufacturing hurdles. Donor variability, cryopreservation, scalability, and equipment choices, including the use of bioreactors, all impact product quality, reproducibility, and regulatory readiness. This workshop explores practical strategies to strengthen manufacturing systems, mitigate risk, and ensure a smooth transition into the clinic.


Join this workshop to:

- Understand how donor variability and cryopreservation affect product quality, and ways to reduce these risks
- Explore scalability, bioreactor implementation, and equipment decisions that drive consistency and compliance
- Review case-based approaches for moving from preclinical data to robust clinical programs

Workshop Leaders



James Liu
Research Scientist
ImmuneBridge



Monica Raimo
Director of
Product & Process
Development
Glycostem

Lunch Break & Networking

12.30

Afternoon Session

1.30 - 4.30

Harnessing Biomarker Discovery & Translational Tools to Accelerate NK Therapy Clinical Success

Advancing NK-based therapies from preclinical proof-of-concept to meaningful clinical outcomes depends on identifying the right patients and monitoring their responses effectively. Predictive biomarkers, translational analytics, and innovative assay platforms are critical to reduce trial risk, guide dosing, and validate therapeutic mechanisms. This workshop explores state-of-the-art strategies to integrate biomarker discovery and translational science into NK therapy development to de-risk programs and speed regulatory and clinical milestones.

Join this workshop to:

- Understand emerging biomarkers for patient selection, persistence, and therapeutic response in autoimmunity and oncology
- Explore cutting-edge analytical tools, single-cell sequencing, spatial transcriptomics, and functional NK assays to uncover actionable insights
- Review case-based examples of how translational strategies can refine trial design, optimize dosing, and improve go/no-go decisions

Workshop Leaders



Adil Duru
Director of
Business
Development
Glycostem



Brian Garrison
Vice President of
Research
Senti Bio



Hongxia Zhang
Independent
Expert

End Pre-Conference Workshop Day

4.30

Conference Day One

Tuesday, March 24



7.30 Registration & Light Breakfast



Stefanie Mandl-Cashman
Chief Scientific Officer
Indapta Therapeutics

8.20 Chair's Opening Remarks

Showcasing Clinical Evidence in Innate Cell Therapies Demonstrating Translational Success, Validating Platforms, & Building Confidence for the Next Phase of Growth

8.30 CEO Think Tank: Defining the Next Era of Innate Therapies Through Insight & Experience

A dynamic opening discussion featuring CEOs and founders at the forefront of innate immunity and NK-cell innovation. This high-level session sets the tone for the meeting as industry leaders examine the current landscape, emerging scientific and commercial inflection points, and the path to translating innate immune breakthroughs into meaningful therapeutic impact. Through candid insights and forward-looking perspectives, the panel will outline the opportunities, challenges, and decisive moves that will shape the field over the next 3–5 years.

- The milestones that brought innate therapies to today's inflection point
- What's driving the next wave of NK and innate innovation
- Scientific and clinical hurdles that must be overcome
- Strategic priorities in a shifting funding and regulatory climate
- Commercial pathways and competitive positioning for the next era



Nina Horowitz
Chief Executive Officer
ImmuneBridge



Yi Jin
Chief Executive Officer
GeCell Therapeutics



Robert Lewis
Chief Executive Officer & Co-Founder
NÖK Therapeutics



Tracy Ryan
Founder
NKore Bio Therapeutics



Adil Duru
Director of Business Development
Glycostem

9.30 Umbilical Cord Blood CD34+ Hematopoietic Stem Cell-Derived Natural Killer Cells in Acute Myeloid Leukaemia – A Phase I Clinical Study

- Demonstrating safety and feasibility of umbilical cord blood-derived CD34 NK cell therapy with no dose-limiting toxicities or GVHD
- Showcasing *in vivo* persistence, activation, and cytotoxicity confirming biological activity in AML patients
- Highlighting preliminary clinical responses with blast reduction and MRD clearance supporting next-phase development



10.00 Moring Break & Speed Networking

Clinical Data Showcase : Spotlighting Positive Data to Drive Further Clinical Momentum

11.00 Durable Long-Term Survival Following Autologous NK-Cell Consolidation in Multiple Myeloma: Phase I Data with Extended Follow-Up

- Sustained Long-Term Survival: Extended follow-up demonstrates significant overall survival benefit signal in ASCT eligible multiple myeloma cohorts
- Clinical Durability in High-Risk Populations: Notably, high-risk cytogenetic features by FISH achieved durable remission and long-term survival, suggesting potential broad therapeutic applicability across risk categories
- Advancement Toward Phase II & Beyond: Data support progression to a phase II trial aimed at confirming CR, PFS, and OS, expanding to multi-center sites, and exploring combination strategies to enhance NK-cell persistence and functional potency



Robert Lewis
Chief Executive Officer & Co-Founder
NÖK Therapeutics

Conference Day One

Tuesday, March 24



Tracy Ryan
Founder
NKore
BioTherapeutics

11.30 Clinical Signals from NKore's Allogeneic sNK Platform Demonstrating Safety, Persistence & Potential Therapeutic Benefit

- Advancing first-in-human safety, early compassionate-use cases show no adverse events in patients treated with NK101, supporting a favorable emerging safety profile ahead of IND submission
- Demonstrating NK-cell persistence and immune engagement, immune-monitoring data show NK-cell levels rising from <2% to ~18% post-infusion in one patient, indicating meaningful *in vivo* activity
- Informing clinical development and indication strategy, early real-world experience is guiding prioritization, dosing, and translational endpoints as NKore moves toward first-in-human trials



12.00 Lunch & Networking

Continuing the Clinical Success Stories & Delving into Strategic Investment to Propel the NK Field



Kanya Rajangam
President, Chief
Medical Officer &
Head of Research &
Development
Senti Bio

1.00 Promising Phase I Clinical Trial Results from SENTI-202-101, a First-in-Class, CD33 and/or FLT3 & not EMCN, Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy in Adults with R/R AML

- SENTI-202 is well tolerated in patients with R/R AML
- SENTI-202 demonstrates promising preliminary efficacy
- Will present data from ≥20 R/R AML patients



1.30 Interactive Roundtables: Building Sustainable Financing Pathways in Innate Therapies

- Long-term success in innate cell therapies requires more than early-stage capital, it depends on sustainable financing strategies that support manufacturing scale-up, clinical progression, and commercial readiness
- This interactive roundtable will bring together participants to explore how companies can structure deals, partnerships, and milestone-driven financing models that appeal to pharma, VCs, and strategic investors alike



2.00 Afternoon Break & Poster Session

Join us for an interactive poster session where leading industry researchers and academic professionals present the latest findings, share insights, and engage in discussions on emerging scientific advances. This session offers an opportunity to explore innovative data, ask questions directly and connect with peers across the field. To find out how you can get involved, visit the website for more details.

Creating Smarter & More Adaptable Innate Immunotherapies that Enhance Tumor Recognition, Improve Safety, & Broaden Access to Transformative Treatments for Patients

3.00 Panel Discussion: Innovation Pathways from Autologous to Allogeneic to *In Vivo*

What's the development roadmap for the next decade in cell and gene therapies, and how do technologies build on one another rather than compete?

- Lessons learned from autologous CAR-T to inform next generation designs
- Accelerating allogeneic platforms into the clinic as scalable, off-the-shelf solutions
- The integration potential: how today's allo approaches can feed into tomorrow's *in vivo* delivery models
- Patient access: how to make sure patients benefit at each stage of this innovation curve



Henri Bayle
Chief Scientific and Development
Officer & Cofounder
NKILT Therapeutics



Chris Horan
Chief Technical Officer
Artiva Bio

Conference Day One

Tuesday, March 24



Nina Horowitz
Chief Executive Officer
ImmuneBridge

4.00 **Harnessing AI & Machine Learning to Unlock New Strategies in Innate Immunotherapy for Faster, More Effective Treatments**

- Applying AI-driven analysis to develop predictive models of donor performance
- Leveraging machine learning models to guide CAR-NK engineering and manufacturing decisions
- Integrating machine learning into preclinical and clinical workflows to continuously improve product efficacy



Stefanie Mandl-Cashman
Chief Scientific Officer
Indapta Therapeutics

4.30 **Chair's Closing Remarks**

4.40 **End of Conference Day One**

■ I like the collaborative atmosphere of the meeting. There was also plenty of time for networking and to learn each other's work closely ■

Director & Assistant Professor, **MD Anderson Cancer Center, University of Texas**

Conference Day Two

Wednesday, March 25



7.30 Light Breakfast & Networking



Stefanie Mandl-Cashman
Chief Scientific Officer
Indapta Therapeutics

8.20 Chair's Opening Remarks

Enhancing the Efficacy & Persistence of NK Cells to Deliver Stronger & More Sustained Anti-Tumor Activity

8.30 Panel Discussion: Optimizing Efficacy & Durability in NK Cell Therapies to Maximize Patient Outcomes

Achieving durable responses in patients remains one of the most important challenges for NK cell therapies. This panel will bring together leaders in academia, biotech, and clinical development to discuss strategies for boosting efficacy, extending persistence, and improving the therapeutic potential of NK-based treatments. Experts will explore how next generation engineering, manufacturing, and clinical insights are shaping the future of innate cell therapies.

- Understanding barriers to efficacy and persistence, examining tumor escape, immunosuppression, and NK cell exhaustion that limit clinical outcomes
- Advancing engineering solutions, exploring cytokine support, gene edits, and checkpoint resistance to strengthen NK cell function *in vivo*
- Improving translation to the clinic, aligning manufacturing, trial design, and biomarker strategies to achieve more consistent and durable responses



Frank Borriello
Chief Executive Officer
Alloplex Biotherapeutics



Yi Jin
Chief Executive Officer
GeCell Therapeutics



Prasad Krishnamurthy
Chief Scientific Officer
East Ocyon Bio



Vasil Galat
Chief Executive &
Scientific Officer
Artec Biotech

9.30 Integrated Preclinical & Metabolic Optimization of NK Cells Derived from Pluripotent Stem Cells & Peripheral Blood

- Comparative characterization of iPSC- and peripheral blood-derived NK cells to define intrinsic phenotypic and metabolic differences
- Functional evaluation of cytotoxicity, persistence, and metabolic adaptability to reveal donor- and source-dependent performance variability
- Metabolic engineering strategies to enhance mitochondrial fitness, delay exhaustion, and improve next-generation NK cell efficacy



10.00 Morning Break & Networking

Optimizing NK Cells to Provide Enhanced Targeting, Potency, Persistence and Safety for more Effective Therapies

11.00 Engineering Cytokine Enhanced NK Cells Boosting Function Extending Persistence Delivering Durable Responses



Yansen Xiao
Postdoctoral
Researcher
University of
Pennsylvania

- Engineering NK cells with cytokine support to sustain proliferation and activity in hostile tumor environments
- Developing membrane-bound or controlled cytokine expression systems to avoid systemic toxicity while boosting local activity
- Advancing self-renewing NK platforms that maintain long-term cytotoxicity and persistence after infusion



Pinaki Prosad Banerjee
Director & Assistant
Professor, Laboratory
of Adoptive Cell
Therapy Platform,
Stem Cell Translational
Research
MD Anderson Cancer
Center, University of
Texas

11.30 Engineering Resilient CAR-NK Cell Therapies, Innovations from the Rezvani Lab to Treat Patients with CAR-NK Therapies More Effectively

- Developing safer and more effective CAR-NK therapies from cord blood to treat a range of cancers from lymphoma leukaemia to breast cancer
- Enhancing NK cell function through gene editing and checkpoint discovery
- Expanding applications to solid tumors with scalable off-the-shelf products

Conference Day Two

Wednesday, March 25



Nick Veomett
Vice President,
Corporate Development
& Program Lead
Artiva
Biotherapeutics

12.30 AlloNK in Autoimmune Disease: Clinical Progress & Translational Insights

- Profile of AlloNK, ability to deeply deplete B-cells, and potential advantages over other modalities
- Early clinical insights from ongoing clinical trials in autoimmune disease
- Process strategies enabling consistency and potency at scale



1.00 Lunch & Networking

Developing New Engineering Approaches Creating Smarter & More Adaptable Immunotherapies that Enhance Tumor Recognition Improve Safety & Broaden Access to Transformative Treatments for Patients



Brian Garrison
Vice President of
Research
Senti Bio

2.00 Promising Phase I Correlative SENTI-202 Data is Consistent with Clinical Activity & Unique Logic Gated Mechanism of Action

- Will present clinical data consistent with SENTI-202 mechanism of action, including:
- CD33 OR FLT3 logic gated CAR approach for targeting both AML blasts and leukemic stem cell NOT EMCN logic gated inhibitory CAR approach for protection of hematopoietic stem and progenitor cells
- Supporting data for SENTI-202 PK, patient disease characterization, and patient responses



Frank Borriello
Chief Executive Officer
Alloplex
Biotherapeutics

2.30 Developing Next-Gen NK Cells to Boost Safety & Potency for More Effective Cancer Therapies

- Developing strategies to enhance NK, persistence, migration, tumor-killing potential and improving safety profiles
- Exploring scalable platforms for making *ex vivo* cell manufacturing more efficient at reduced cost



Neil Sheppard
Director of Research
Technologies &
Innovation at the
Center for Cellular
Immunotherapies
University of
Pennsylvania

3.00 Multiplex Engineering of NK Cells to Resist the Tumor Microenvironment for More Effective Activity & Therefore More Successful Therapies

- Disarming immune suppression by engineering NK cells to resist inhibitory signals
- Overcoming NK cell-intrinsic checkpoints to boost NK metabolism and functional activity
- Combining multiplex base editing and CAR and cytokine engineering to enhance activity to antigen positive and negative tumors



Stefanie Mandl-Cashman
Chief Scientific Officer
Indapta Therapeutics

3.30 Chair's Closing Remarks

3.45 End of the 11th Innate Killer Summit

Take the Spotlight & Partner with the 11th Innate Killer Summit



11th Annual Innate Killer Summit

March 23-25, 2026 | San Diego, CA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Driving the Next Wave of NK Cell Breakthroughs Through Partnership

As the go-to forum uniting all modalities of NK therapy developers, the **11th Annual Innate Killer Summit** is your one-stop-shop to connect with strategic decision makers and pioneers in the innate landscape, grow your relationships and establish yourself as a key expert in this reinvigorated field.

With many trailblazers entering the clinic this year, tight-knit partnerships and effective solutions are critical to accelerating progress in **manufacturing, genetic engineering, biomarker development, optimal instrumentation, culture media**, and more. This is a one-of-a-kind opportunity to collaborate with stakeholders looking for reliable partners to accelerate their end-to-end development of NK cell therapies.



Position Your Solutions at the Premier Annual Gathering for NK Cell Therapy Leaders

Showcase your innovations directly at the most established and longest-running NK-focused meeting globally. With 11 years of trusted reputation, this summit brings together the exact stakeholders who are actively searching for cutting-edge tools, platforms, and services to accelerate their NK programs.



Connect with an NK-Focused Audience Actively Seeking Enabling Technologies


Engage with a concentrated group of NK developers, scientists, heads of R&D, process experts, and technical decision-makers, who attend specifically to discover new partners, platforms, CMOs, cell sorting devices, gene engineering technologies, raw materials, and analytical assays, that can accelerate their NK programs.



Elevate Your Brand Alongside the Field's Leading Innovators


Align with the foremost voices advancing NK and innate cell therapy. Reinforce your leadership, expand market visibility, and create high-value collaborations in a space experiencing rapid scientific and commercial growth, with companies that need trusted and reliable providers to help unveil the true potential of NK therapies.

Type of Companies Attending



Statistics taken from the 10th Innate Killer Summit*

Type of Companies Attending



Statistics taken from the 10th Innate Killer Summit*

Get Involved



Jake Bennett
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book



www.innate-killer.com/register



Tel: +1 (617) 455-4188



Email: info@hansonwade.com



Discover how biotech, pharma, and academia are advancing NK and innate cell therapies, showcasing new clinical data, *in vivo* strategies, engineering innovations, and manufacturing progress driving next-generation efficacy and scalability.



Build a clear view of NK development challenges and solutions, from biomarkers and trial design to donor variability, allogeneic scale-up, and translational readiness, spanning early discovery to clinical execution.



Engage with the global NK community to connect with innovators and form collaborations with biotech leaders, clinicians, academics, and solution providers accelerating safer, more durable, and accessible therapies.

Drug Developers	Register by Friday, December 19 & Save up to \$1,000	On the Door Price
Conference + Workshop Day	\$2,697 (Save \$1,000)	\$3,697
Conference Only	\$2,199 (Save \$500)	\$2,699

Academic & Research Institutes**	Register by Friday, December 19 & Save up to \$1,000	On the Door Price
Conference + Workshop Day	\$2,297 (Save \$750)	\$3,047
Conference Only	\$1,799 (Save \$500)	\$2,299

Solution & Service Providers	Register by Friday, December 19 & Save up to \$1,000	On the Door Price
Conference + Workshop Day	\$4,397 (Save \$1,000)	\$5,397
Conference Only	\$3,399 (Save \$500)	\$3,899

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic and research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts***

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

Westin San Diego Bayview

1051 Columbia St, San Diego, CA 92101, United States

www.marriott.com/en-us/hotels/sanws-the-westin-san-diego-bayview/overview/

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom



+1 (617) 455-4188

@ info@hansonwade.com

www.innate-killer.com

Cell & Gene Therapy Event Series



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE